China is making a pretty direct play for global drugmakers – and doing it out in the open.
Last week, Commerce Minister Wang Wentao brought together senior pharma execs, alongside PhRMA CEO Stephen Ubl, to underscore Beijing’s effort to cement biopharma as a pillar industry under its next Five‑Year Plan. In parallel meetings, Wang urged Eli Lilly to “deepen its commitment” to China, citing market access, intellectual property protections, and regulatory predictability as incentives for long‑term investment.
The outreach comes amid a profound shift in the global drug development landscape. China has rapidly emerged as a second hub of pharmaceutical innovation – no longer just a manufacturing base, but a source of early‑stage science and clinical data increasingly shaping global pipelines.
U.S. policymakers are taking note. Capitol Hill has grown unusually unified around concerns that China’s expanding footprint – spanning R&D, clinical trials and out‑licensing of novel assets – could erode U.S. leadership in the biopharma sector if left unchecked.
Yet decoupling is easier said than done. U.S. drugmakers continue to turn to China for cost‑efficient development and pipeline replenishment, even as tariffs, biosecurity legislation and geopolitical rhetoric intensify. Experts caution that trade barriers alone are unlikely to unwind deeply integrated drug supply and innovation networks and could ultimately slow progress on both sides.
The result is a new world order in biopharma: one defined less by clean separation than by strategic tension, selective collaboration and a growing imperative for policymakers to balance competition with patient access.
– Stephen Tellone, Associate Director
